| Imunus Aurobindo, the exclusive antiviral division of
Aurobindo Pharma Ltd., has launched once daily NNRTI, Efavirenz (VIRANZ) and a unique protease
inhibitor Nelfinavir (NELVEX). With this, Aurobindo Pharma becomes the first Indian company to
launch these two antiretrovirals. Efavirenz is a
strongly recommended first line NNRTI with excellent efficacy and tolerance. Efavirenz
(VIRANZ) has once daily dose advantage unlike NNRTIs like Nevirapine.
Efavirenz (VIRANZ), the NNRTI would be available at a very
economical price compared to the international brands available in the Indian market.
NELVEX has potent advantages compared to Indinavir (currently
available) due to its compatibility in combinations and lesser side effects in the long-term
therapy.
Imunus Aurobindo is introducing the best protease inhibitor
(PI) - Nelfinavir (NELVEX) - at prices on par with Indinavir and much lower than the
exorbitant prices of international PI brands.
"We
are sure that these two antiretrovirals will equip the anti-AIDS therapeutic armamentarium of
many clinicians. With these new additions, Aurobindo Pharma has the largest number of
antiretroviral molecules for treating AIDS", said
Mr. S. Hariharan, Vice President, Imunus Aurobindo. |
PRESS
ROOM 
